AMICUS THERAPEUTICS, INC. Deferred Tax Assets, in Process Research and Development
AMICUS THERAPEUTICS, INC. had Deferred Tax Assets, in Process Research and Development of $20.63 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-02-20
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $20.63M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $34.88M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $34.42M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $29.32M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $20.63M 10-K · filed 2026-02-20 |
| 2024-12-31 | $34.88M 10-K · filed 2026-02-20 |
| 2023-12-31 | $34.42M 10-K · filed 2025-02-19 |
| 2022-12-31 | $29.32M 10-K · filed 2024-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |